AlkermesALKS
About: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Employees: 1,800
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
31% more repeat investments, than reductions
Existing positions increased: 152 | Existing positions reduced: 116
23% more call options, than puts
Call options by funds: $8.45M | Put options by funds: $6.88M
2.36% less ownership
Funds ownership: 104.68% [Q1] → 102.31% (-2.36%) [Q2]
7% less funds holding
Funds holding: 368 [Q1] → 344 (-24) [Q2]
14% less capital invested
Capital invested by funds: $5.62B [Q1] → $4.83B (-$793M) [Q2]
25% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 55
33% less funds holding in top 10
Funds holding in top 10: 6 [Q1] → 4 (-2) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
RBC Capital Leonid Timashev | 46%upside $42 | Sector Perform Maintained | 30 Jul 2025 |
Needham Ami Fadia | 56%upside $45 | Buy Reiterated | 29 Jul 2025 |
HC Wainwright & Co. Douglas Tsao | 60%upside $46 | Neutral Reiterated | 21 Jul 2025 |
Goldman Sachs Andrea Newkirk | 49%upside $43 | Buy Initiated | 15 Jul 2025 |
UBS Ashwani Verma | 46%upside $42 | Buy Upgraded | 17 Jun 2025 |
Financial journalist opinion
Based on 8 articles about ALKS published over the past 30 days
